title: [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
abstract: Androgen deprivation therapy represents an important part of the management of prostate cancer. However, epidemiological data have shown that it is a well-established cause of osteoporosis and increased risk of fracture. So far no consensus guidelines have been published regarding the screening and treatment of osteoporosis in men with prostate cancer. Here we report the design of a new questionnaire, derived from the FRAX(®) ("Fracture Risk Assessment Tool") algorithm, to evaluate the risk of fracture in those patients. In accordance with recent reviews and on the basis of their experience, our French board of experts recommends systematic screening for osteoporosis with dual energy x- ray absorptiometry scans, practice of exercise and calcium and vitamin D supplementation, and selective treatment with bisphosphonates in men at greatest osteoporotic risk.
authors.affiliation: Service de Rhumatologie, Centre Hospitalier Universitaire, 59000 Lille, France. bernard.cortet@chru-lille.fr
authors.forename: B
authors.initials: B
authors.lastname: Cortet
authors.forename: E
authors.initials: E
authors.lastname: Lartigau
authors.forename: A
authors.initials: A
authors.lastname: Caty
authors.forename: F
authors.initials: F
authors.lastname: Moulinier
authors.forename: F
authors.initials: F
authors.lastname: Staerman
authors.forename: J
authors.initials: J
authors.lastname: Villamizar-Vesga
authors.forename: A
authors.initials: A
authors.lastname: Villers
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000453:epidemiology*; D058866:Osteoporotic Fractures / Q000139:chemically induced / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D018570:Risk Assessment; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists